Bortezomib Completed Phase 1 Trials for Stage IV Adult Diffuse Large Cell Lymphoma / Intraocular Lymphoma / Stage III Grade 2 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / Unspecified Adult Solid Tumor, Protocol Specific / Stage IV Adult Lymphoblastic Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Stage IV Adult T-Cell Leukemia/Lymphoma / Stage III Adult Diffuse Large Cell Lymphoma / Stage III Mycosis Fungoides/Sezary Syndrome / Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / Recurrent Adult Immunoblastic Large Cell Lymphoma / Stage IV Adult Diffuse Small Cleaved Cell Lymphoma / Post Transplant Lymphoproliferative Disorder / Stage III Adult Burkitt Lymphoma / Recurrent Adult Lymphoblastic Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Stage IV Adult Hodgkin Lymphoma / Stage III Mantle Cell Lymphoma / Stage IV Cutaneous T-Cell Non-Hodgkin Lymphoma / Stage IV Marginal Zone Lymphoma / Splenic Marginal Zone Lymphoma / Recurrent Adult Diffuse Mixed Cell Lymphoma / Stage IV Grade 1 Follicular Lymphoma / Stage IV Mycosis Fungoides/Sezary Syndrome / Waldenström's Macroglobulinemia (WM) / Recurrent Marginal Zone Lymphoma / Stage III Grade 3 Follicular Lymphoma / Primary Central Nervous System Hodgkin Lymphoma / Stage IV Grade 2 Follicular Lymphoma / Primary Central Nervous System Non-Hodgkin Lymphoma / Stage III Adult Lymphoblastic Lymphoma / Stage IV Adult Burkitt Lymphoma / Recurrent Adult Burkitt Lymphoma / Recurrent Small Lymphocytic Lymphoma / Angioimmunoblastic T-Cell Lymphoma / Stage III Adult Diffuse Small Cleaved Cell Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Stage III Marginal Zone Lymphoma / Stage IV Adult Immunoblastic Large Cell Lymphoma / Recurrent Adult Grade III Lymphomatoid Granulomatosis / Stage IV Grade 3 Follicular Lymphoma / Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma / Stage III Adult Diffuse Mixed Cell Lymphoma / Adult Grade III Lymphomatoid Granulomatosis / Recurrent Adult T-Cell Leukemia/Lymphoma / Stage IV Adult Diffuse Mixed Cell Lymphoma / Stage III Cutaneous T-Cell Non-Hodgkin Lymphoma / Recurrent Mycosis Fungoides/Sezary Syndrome / Stage III Adult Hodgkin Lymphoma / Stage III Small Lymphocytic Lymphoma / Recurrent Adult Hodgkin's Lymphoma / Anaplastic Large Cell Lymphoma / Stage III Grade 1 Follicular Lymphoma / Stage IV Small Lymphocytic Lymphoma / Nodal marginal zone B-cell lymphomas / Stage IV Mantle Cell Lymphoma / Recurrent Adult Diffuse Small Cleaved Cell Lymphoma / Stage III Adult Immunoblastic Large Cell Lymphoma / Stage III Adult T-Cell Leukemia/Lymphoma Treatment

IndicationsStatusPurposePhase
CompletedTreatment1
clinicaltrials.gov IdentifierTitleDrugs
NCT00348985PXD101 and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas
NCT00290680Bortezomib and Celecoxib in Treating Patients With Advanced Solid Tumors
NCT00541359Bortezomib and Topotecan Hydrochloride in Treating Patients With Advanced Solid Tumors
NCT00007878Bortezomib, Fluorouracil, and Leucovorin Calcium in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed By Surgery
NCT00030368Bortezomib and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Solid Tumors
NCT00028587PS-341 and Combination Chemotherapy in Treating Patients With Advanced Solid Tumors
NCT00023855PS-341 and Doxorubicin in Treating Patients With Advanced Solid Tumors
NCT00027898Bortezomib and Combination Chemotherapy in Treating Patients With Advanced Solid Tumors
NCT00068484A Dose Finding Phase I Trial of the Combination of Topotecan and PS-341, a Novel Proteasome Inhibitor, in Advanced Malignancies
NCT00227513Vorinostat and Bortezomib in Treating Patients With Metastatic or Unresectable Solid Tumors